0QAJ Stock Overview A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
DBV Technologies S.A. Competitors Price History & Performance
Summary of share price highs, lows and changes for DBV Technologies Historical stock prices Current Share Price €0.63 52 Week High €1.90 52 Week Low €0.51 Beta 0.79 1 Month Change -5.44% 3 Month Change -9.74% 1 Year Change -65.82% 3 Year Change -80.53% 5 Year Change -96.87% Change since IPO -94.18%
Recent News & Updates
DBV Technologies Regains Compliance with Nasdaq Listing Rule 5550(a)(2) Dec 17
DBV Technologies Announces Plan to Implement ADS Ratio Change to Regain Compliance Nov 12
Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.17 loss in 3Q 2023) Nov 08
New major risk - Revenue and earnings growth Oct 23
Dbv Technologies Announces Positive Regulatory Updates for the Viaskin Peanut Patch in the United States and Europe Oct 23
Second quarter 2024 earnings released: US$0.34 loss per share (vs US$0.26 loss in 2Q 2023) Jul 31 See more updates
DBV Technologies Regains Compliance with Nasdaq Listing Rule 5550(a)(2) Dec 17
DBV Technologies Announces Plan to Implement ADS Ratio Change to Regain Compliance Nov 12
Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.17 loss in 3Q 2023) Nov 08
New major risk - Revenue and earnings growth Oct 23
Dbv Technologies Announces Positive Regulatory Updates for the Viaskin Peanut Patch in the United States and Europe Oct 23
Second quarter 2024 earnings released: US$0.34 loss per share (vs US$0.26 loss in 2Q 2023) Jul 31
DBV Technologies S.A. to Report Q2, 2024 Results on Jul 30, 2024 Jul 29
New minor risk - Share price stability Jul 22
DBV Technologies Provides Non-Compliance Update Related to Nasdaq Listing Rule 5550(a)(2) & 5810(c)(3)(A) Jun 20
New minor risk - Market cap size Jun 15
First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.22 loss in 1Q 2023) May 08
New major risk - Revenue and earnings growth May 08
No longer forecast to breakeven May 08
Insufficient new directors Apr 01
DBV Technologies S.A., Annual General Meeting, May 16, 2024 Mar 25
New minor risk - Profitability Mar 15
No longer forecast to breakeven Mar 15
Full year 2023 earnings released: US$0.77 loss per share (vs US$1.24 loss in FY 2022) Mar 09
New major risk - Financial position Mar 08
DBV Technologies S.A. to Report Fiscal Year 2023 Results on Mar 07, 2024 Mar 05
New minor risk - Share price stability Feb 20
Forecast to breakeven in 2026 Dec 31
DBV Technologies Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market Dec 22
DBV Technologies S.A. to Present New Data at ACAAI 2023 Nov 03
Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.18 loss in 3Q 2022) Nov 02
DBV Technologies S.A. to Report Q3, 2023 Results on Oct 31, 2023 Oct 28
DBV Technologies S.A. Announces Executive Changes Oct 18 DBV Technologies S.A. Announces Executive Changes
Dbv Technologies S.A. Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies Aug 02
Second quarter 2023 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2022) Aug 01
DBV Technologies S.A. to Report First Half, 2023 Results on Jul 31, 2023 Jul 26
New minor risk - Shareholder dilution Jul 26
First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.30 loss in 1Q 2022) May 07 Mar 03
Full year 2022 earnings released: US$1.24 loss per share (vs US$1.78 loss in FY 2021) Mar 03
Forecast to breakeven in 2025 Jan 04
DBV Technologies Announces FDA Lifts Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial Dec 23
Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.44 loss in 3Q 2021) Nov 05
DBV Technologies S.A. Announces Executive Changes Oct 05
DBV Technologies S.A. Receives Feedback from the U.S. Food and Drug Administration in the Form of a Partial Clinical Hold on Its VITESSE Phase 3 Clinical Study Sep 23
DBV Technologies S.A. Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years Sep 08
Second quarter 2022 earnings released: US$0.35 loss per share (vs US$0.56 loss in 2Q 2021) Aug 02 DBV Technologies S.A. announced that it has received €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, Fairmount Funds Management LLC Jun 14
DBV Technologies S.A. announced that it expects to receive €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, and other investor Jun 11
DBV Technologies S.A. announced that it expects to receive €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, and other investor Jun 10
DBV Technologies Announces Positive Topline Results from Phase 3 Epitope Trial of Viaskin Peanut in Peanut-Allergic Toddlers Jun 08
First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.54 loss in 1Q 2021) May 03
High number of new directors Apr 27
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 05
No longer forecast to breakeven Mar 04 DBV Technologies S.A. to Report Q1, 2022 Results on May 02, 2022
DBV Technologies S.A. Provides Update on Investigational Viaskin Peanut Dec 21
Third quarter 2021 earnings released: US$0.44 loss per share (vs US$0.56 loss in 3Q 2020) Oct 29
Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.88 loss in 2Q 2020) Aug 04
Independent Director has left the company May 26
First quarter 2021 earnings released: US$0.54 loss per share (vs US$0.89 loss in 1Q 2020) May 04
Revenue misses expectations Mar 13
DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer Feb 22 DBV Technologies S.A. to Report First Half, 2021 Results on Aug 02, 2021
DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years Jan 16
New 90-day high: €5.58 Jan 06
New 90-day high: €4.41 Dec 04
Hugh Sampson Decides to Step Down as Chief Scientific Officer of DBV Technologies, Effective December 1, 2020 Nov 24
New 90-day high: €4.21 Nov 11
DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020 Nov 10
DBV Technologies S.A. Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency Nov 02
New 90-day low: €2.79 Oct 15
New 90-day low: €3.37 Sep 19
New 90-day low - €3.71 Aug 27
New 90-day low - €4.13 Aug 04 Shareholder Returns 0QAJ GB Biotechs GB Market 7D 3.2% 1.4% 0.2% 1Y -65.8% -25.1% 2.3%
See full shareholder returns
Return vs Industry: 0QAJ underperformed the UK Biotechs industry which returned -25.1% over the past year.
Return vs Market: 0QAJ underperformed the UK Market which returned 2.3% over the past year.
Price Volatility Is 0QAJ's price volatile compared to industry and market? 0QAJ volatility 0QAJ Average Weekly Movement 15.4% Biotechs Industry Average Movement 10.0% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.4% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0QAJ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0QAJ's weekly volatility has increased from 10% to 15% over the past year.
About the Company DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.
Show more DBV Technologies S.A. Fundamentals Summary How do DBV Technologies's earnings and revenue compare to its market cap? 0QAJ fundamental statistics Market cap €60.80m Earnings (TTM ) -€98.10m Revenue (TTM ) €12.03m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0QAJ income statement (TTM ) Revenue US$12.52m Cost of Revenue US$0 Gross Profit US$12.52m Other Expenses US$114.60m Earnings -US$102.09m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.06 Gross Margin 100.00% Net Profit Margin -815.73% Debt/Equity Ratio 0%
How did 0QAJ perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/31 18:00 End of Day Share Price 2024/12/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources DBV Technologies S.A. is covered by 18 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Tazeen Ahmad BofA Global Research Jean-Jacques Le Fur Bryan Garnier & Co Andrew Peters Deutsche Bank
Show 15 more analysts 
